UTA.09703.HCMJp

General

Cell Line

hPSCreg Name
TAUi001-A
Alternative name(s)
UTA.09703.HCMJp
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
Last update 19th April 2022
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Tampere University (TAU)
Derivation country Finland

External Databases

BioSamples SAMEA6880673
Cellosaurus CVCL_ZA77
CLO CLO_0102531
Wikidata Q98133169

General Information

* Is the cell line readily obtainable for third parties?
Yes
Cell line can only be used in: Fit4purpose-OOC project
Research use: allowed
Clinical use: not allowed
Commercial use: allowed
Subclones

Donor Information

General Donor Information

Sex male
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
hypertrophic cardiomyopathy
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Asymmetric Septal Hypertrophies
  • Hypertrophic Obstructive Cardiomyopathies
  • Cardiomyopathy, hypertrophic
  • Subvalvular Stenosis, Idiopathic Hypertrophic
  • Hypertrophic Obstructive Cardiomyopathy
  • HYPERTR OBSTR CARDIOMYOP
  • hyper. obst. cardiomyopathy
  • SUBVALV STENOSIS
  • HCM - Hypertrophic cardiomyopathy
  • IDIOPATHIC HYPERTROPHIC SUBVALV STENOSIS
  • Obstructive Cardiomyopathy, Hypertrophic
  • Hypertrophies, Asymmetric Septal
  • Hypertrophic Cardiomyopathies
  • Cardiomyopathies, Hypertrophic Obstructive
  • Hypertrophic cardiomyopathy (disorder)
  • HOCM - Hypertrophic obstructive cardiomyopathy
  • Primary hypertrophic cardiomyopathy
  • Idiopathic Hypertrophic Subvalvular Stenosis
  • IHSS
  • primary hypertrophic cardiomyopathy (disorder) [Ambiguous]
  • Idiopathic Hypertrophic Subaortic Stenosis
  • Obstructive cardiomyopathy
  • SUBVALV STENOSIS IDIOPATHIC HYPERTROPHIC
  • Hypertrophy, Asymmetric Septal
  • Hypertrophic obstructive cardiomyopathy (disorder)
  • Septal Hypertrophy, Asymmetric
  • Cardiomyopathies, Hypertrophic
  • IHSSs
  • hypertrophic myocardiopathy
  • Cardiomyopathy, Hypertrophic Obstructive
  • HCM
  • Obstructive Cardiomyopathies, Hypertrophic
  • Asymmetric Septal Hypertrophy
  • Septal Hypertrophies, Asymmetric
  • hypertrophic subaortic stenosis
  • obstructive hypertrophic cardiomyopathy
  • hypertrophic obstructive cardiomyopathy
  • hypertrophic cardiomyopathy
show more synonyms
Genetic variants
JPH2 (target)
q13.12.
NM_020433.5:c.482C>A
NP_065166.2:p.(Thr161Lys)
Heterozygous
JPH2 mutation c.482C>A (p.T161K)

Karyotyping (Donor)

Has the donor karyotype been analysed?
No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA6880674

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent pertain to a specific research project? No
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? Yes
How may genetic information associated with the cell line be accessed? No information
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Ethics Committee of Pirkanmaa Hospital District
Approval number R08070
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
skin fibroblast
Collected in 2012

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Selection criteria for clones Morphology
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Gelatin
Feeder cells CF-1 MEF MITC
Cellfinder Ont Id: CELDA_00007731
Passage method Enzymatically
Collagenase
CO2 Concentration 5 %
Medium Other medium:
Base medium: KO-DMEM
Main protein source: Knock-out serum replacement
Serum concentration: 20 %
Supplements
NEA %
FGF
β-mercaptoethanol
Pen/Strep
Glutamax
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
SOX2
Yes
NANOG
Yes
ZFP42 (REX-1)
Yes
c-MYC
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
Sox17
Yes
AFP
Yes
Protocol or reference
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
KDR
Yes
ACTC1 - alpha cardiac actinin
Yes
Protocol or reference
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
SOX1
Yes
PAX6
Yes
Protocol or reference

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46XY
Passage number: 12
Karyotyping method: KaryoLite BoBs

Other Genotyping (Cell Line)